101 related articles for article (PubMed ID: 10527267)
1. Immune regulation in multiple myeloma: the host-tumour conflict.
Cook G; Campbell JD
Blood Rev; 1999 Sep; 13(3):151-62. PubMed ID: 10527267
[TBL] [Abstract][Full Text] [Related]
2. Cellular immunotherapy for multiple myeloma.
Rosenblatt J; Avigan D
Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
[TBL] [Abstract][Full Text] [Related]
3. Immunodeficiency and immunotherapy in multiple myeloma.
Pratt G; Goodyear O; Moss P
Br J Haematol; 2007 Sep; 138(5):563-79. PubMed ID: 17686051
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
5. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
8. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
9. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress.
Byrne SN; Halliday GM
Cancer Immunol Immunother; 2003 Jun; 52(6):396-402. PubMed ID: 12739069
[TBL] [Abstract][Full Text] [Related]
10. Advances in the biology of multiple myeloma: therapeutic applications.
Anderson K
Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
[TBL] [Abstract][Full Text] [Related]
11. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
12. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
14. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
15. Immune properties of human umbilical cord Wharton's jelly-derived cells.
Weiss ML; Anderson C; Medicetty S; Seshareddy KB; Weiss RJ; VanderWerff I; Troyer D; McIntosh KR
Stem Cells; 2008 Nov; 26(11):2865-74. PubMed ID: 18703664
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
17. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
18. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
19. The immune system--is it relevant to cancer development, progression and treatment?
Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
[TBL] [Abstract][Full Text] [Related]
20. Current concepts in immunotherapy for the treatment of colorectal cancer.
Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
